CN110634567A - System for assessing risk of carbohydrate metabolism and diabetic complications - Google Patents
System for assessing risk of carbohydrate metabolism and diabetic complications Download PDFInfo
- Publication number
- CN110634567A CN110634567A CN201810645169.0A CN201810645169A CN110634567A CN 110634567 A CN110634567 A CN 110634567A CN 201810645169 A CN201810645169 A CN 201810645169A CN 110634567 A CN110634567 A CN 110634567A
- Authority
- CN
- China
- Prior art keywords
- level
- measuring unit
- organism
- vitamin
- determination unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 10
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 10
- 230000023852 carbohydrate metabolic process Effects 0.000 title description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 title description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002207 metabolite Substances 0.000 claims abstract description 22
- 210000003205 muscle Anatomy 0.000 claims abstract description 18
- 239000011573 trace mineral Substances 0.000 claims abstract description 17
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 102000004877 Insulin Human genes 0.000 claims abstract description 15
- 108090001061 Insulin Proteins 0.000 claims abstract description 15
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 15
- 229940125396 insulin Drugs 0.000 claims abstract description 15
- 210000004185 liver Anatomy 0.000 claims abstract description 15
- 230000013595 glycosylation Effects 0.000 claims abstract description 14
- 230000004060 metabolic process Effects 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 13
- -1 oxygen free radical Chemical class 0.000 claims abstract description 12
- 210000000496 pancreas Anatomy 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- 230000004153 glucose metabolism Effects 0.000 claims abstract description 10
- 210000001519 tissue Anatomy 0.000 claims description 23
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 239000011591 potassium Substances 0.000 claims description 12
- 229910052700 potassium Inorganic materials 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 229930003270 Vitamin B Natural products 0.000 claims description 8
- 235000019156 vitamin B Nutrition 0.000 claims description 8
- 239000011720 vitamin B Substances 0.000 claims description 8
- 239000011572 manganese Substances 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011651 chromium Substances 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000008280 blood Substances 0.000 abstract description 45
- 210000004369 blood Anatomy 0.000 abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 31
- 235000000346 sugar Nutrition 0.000 abstract description 27
- 230000002503 metabolic effect Effects 0.000 abstract description 23
- 238000011156 evaluation Methods 0.000 abstract description 10
- 239000007795 chemical reaction product Substances 0.000 abstract description 8
- 239000000047 product Substances 0.000 abstract description 8
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 238000012502 risk assessment Methods 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 4
- 150000003254 radicals Chemical class 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 230000006870 function Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001627 detrimental effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 240000004658 Medicago sativa Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001931 thermography Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000019007 dietary guidelines Nutrition 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000004203 pancreatic function Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000021661 Elimination disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000011871 bio-impedance analysis Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Abstract
The present invention relates to the field of diabetes risk assessment, in particular to a system for assessing the risk of glucose metabolism and diabetic complications. The system comprises: the device comprises an organism oxygen free radical level measuring unit (1), an organism metabolite vitamin level measuring unit (2) and an organism metabolite microelement level measuring unit (3). The invention comprehensively evaluates and analyzes the free radical level, the vitamin level and the trace element level in the metabolic products of the organism through a comprehensive evaluation mode and a single-factor, multi-angle and multi-direction system comprehensive evaluation analysis, and preferably combines a plurality of data such as liver and pancreas bioactivity values, interstitial insulin levels, glycosylation end product values, heat metabolism levels, muscle fat ratios and the like, thereby providing scientific data support for predicting the fluctuation of blood sugar, being beneficial to knowing the blood sugar change in advance and providing great help for avoiding diabetes and complications thereof.
Description
Technical Field
The invention relates to the field of diabetes risk assessment, in particular to a system for assessing risks of glucose metabolism and diabetic complications.
Background
Diabetes mellitus is the first of various chronic diseases due to high morbidity and mortality, and early diagnosis and treatment are greatly difficult due to the hidden morbidity and various serious complications. Numerous studies have shown that the use of blood-based tests alone is far from adequate in the management of pre-diabetes or in the diabetic phase. Therefore, it is necessary to provide a means for effectively and accurately evaluating the trend of blood glucose increase and diabetes in advance.
Disclosure of Invention
The invention aims to overcome the problems in the prior art and provide a system for evaluating the risks of glucose metabolism and diabetic complications, which can take multiple indexes into consideration to comprehensively evaluate the blood glucose rise and the diabetic morbidity risk.
In order to achieve the above object, the present invention provides a system for assessing risk of glucose metabolism and diabetic complications, the system comprising: the device comprises an organism oxygen free radical level measuring unit, an organism metabolite vitamin level measuring unit and an organism metabolite microelement level measuring unit.
Preferably, the vitamin level determination unit in the body metabolites comprises a vitamin B group level determination module.
Preferably, the determination unit for the level of trace elements in the metabolic products of the organism comprises a zinc element level determination module.
Preferably, the determination unit for the level of trace elements in the metabolic products of the organism comprises a potassium element level determination module.
Preferably, the determination unit for the level of trace elements in the metabolic products of the organism comprises a magnesium element level determination module.
Preferably, the determination unit for the level of the trace elements in the metabolic products of the organism comprises a manganese element level determination module.
Preferably, the determination unit for the level of trace elements in the metabolic products of the organism comprises a chromium element level determination module.
Preferably, the system further comprises: a biological activity measuring unit and/or an interstitial insulin level measuring unit of the liver and/or the pancreas.
Preferably, the system further comprises: and a glycosylation detection unit for body tissues.
Preferably, the system further comprises: a body tissue metabolism heat measuring unit and/or a body muscle and/or fat level measuring unit.
The system of the invention can obtain the following beneficial effects:
the evaluation of blood sugar rise at home and abroad is usually carried out by blood examination, but blood drawing causes damage to the organism, and particularly under the premise of unclear blood sugar level rise, some diabetic patients are easy to infect. Or the method is single in the aspect of evaluating the risk of blood sugar rise, and insufficient data support is lacked for comprehensively evaluating the risk of blood sugar rise and diabetes. The invention comprehensively evaluates and analyzes the free radical level, the vitamin level and the trace element level in the metabolic products of the organism through a comprehensive evaluation mode and a single-factor, multi-angle and multi-direction system comprehensive evaluation analysis, and preferably combines a plurality of data such as liver and pancreas bioactivity values, interstitial insulin levels, glycosylation end product values, heat metabolism levels, muscle fat ratios and the like, thereby providing scientific data support for predicting the capability of regulating blood sugar of a human body, being beneficial to knowing the blood sugar change in advance and providing great help for avoiding diabetes and complications thereof.
Drawings
FIG. 1 is a system for assessing the risk of glucose metabolism and diabetic complications provided by the present invention.
Description of the reference numerals
1 body oxygen free radical level measuring Unit
2 vitamin level determination unit in organism metabolite
3 measuring unit for trace element level in organism metabolite
4 biological Activity measurement Unit of liver and/or pancreas
5 interstitial insulin level measurement unit
6 glycosylation detection unit for body tissues
7 body tissue metabolism heat measuring unit
8 muscle and/or fat level determination unit
Detailed Description
The following detailed description of embodiments of the invention refers to the accompanying drawings. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
As shown in fig. 1, the present invention provides a system for assessing the risk of glucose metabolism and diabetic complications, the system comprising: the device comprises an organism oxygen free radical level measuring unit 1, an organism metabolite vitamin level measuring unit 2 and an organism metabolite microelement level measuring unit 3.
Body oxygen free radical level measuring unit 1
According to the invention, the oxygen radicals mainly comprise ONOOH (peroxynitrite radical), NO (nitric oxide radical), H2O2(hydrogen peroxide radical), O2- (superoxide anion), OH- (hydroxyl radical) are elevated. The invention requires that N.ltoreq.+ 10, deviations from this range suggest the potential for causing elevated blood glucose.
The level of oxygen radicals may be tested according to the present invention using methods conventional in the art, preferably, using a bioelectrical detection system.
Vitamin level determination unit 2 in organism metabolites
According to the invention, the vitamin level determination unit 2 in the body metabolites can be a vitamin B group level determination module.
Wherein, the metabolite can be hair, urine, etc.
The vitamin B group functions as a coenzyme in the human body. They promote chemical reactions between conventional enzymes and other compounds to initiate many body functions. The invention finds that the level of vitamin B in the metabolite can reflect the blood sugar level. The normal ranges of vitamin B specified in the present invention are: n is more than 40 and less than 100; if the normal range is exceeded, it means that the risk of blood glucose fluctuation is gradually increased, and the larger the magnitude of the index fluctuation, the higher the risk of blood glucose fluctuation.
Trace element level measuring unit 3
According to the invention, the determination unit 3 for the level of trace elements in the metabolic products of the organism comprises at least one module of a zinc element level determination module, a potassium element level determination module, a magnesium element level determination module, a manganese element level determination module and a chromium element level determination module.
Zinc element level measuring module
The zinc element is related to the activity of enzyme and the metabolism of vitamin; involved in the synthesis of lipids, proteins, nucleic acids, etc.; the zinc element is less than 50, which means that the human body is lack of zinc for a long time, and the zinc element is more than 100, which means that the human body takes too much zinc in a short time or the utilization rate of the zinc in the human body is not high. Both too high and too low values were found to be detrimental to blood glucose regulation.
Potassium element level measuring module
The potassium element is involved in intracellular protein metabolism. Potassium element is less than 50, which means that the human body is lack of potassium for a long time, and potassium element is more than 100, which means that the human body takes too much potassium in a short time or the utilization rate of potassium in the human body is not high. It was found that both too high and too low values of elemental potassium levels are detrimental to blood glucose regulation.
Magnesium element level measuring module
Magnesium element regulates adrenal gland, oxygen and energy and participates in energy metabolism in vivo; magnesium element < 50, which means that the human body is lack of magnesium for a long time, and magnesium element > 100, which means that the human body takes too much magnesium in a short time or the utilization rate of magnesium in the human body is not high. It was found that both too high and too low values of elemental magnesium levels are detrimental to blood glucose regulation.
Manganese element level measuring module
Manganese is involved in the synthesis of enzyme, protein and vitamin B, C, E; activating and metabolizing fat in vivo. Manganese element is less than 50, which means that the human body is lack of manganese for a long time, and manganese element is more than 100, which means that the human body takes too much manganese in a short time or the utilization rate of manganese in the human body is not high. It was found that both too high and too low values of elemental manganese levels are detrimental to blood glucose regulation.
Chromium element level measuring module
Chromium element participates in fat and protein metabolism, combines with nicotinic acid, glutamic acid and the like to form glucose tolerance factor, and has the function of promoting insulin; increasing cholesterol decomposition and excretion, reducing blood cholesterol level, and relieving arteriosclerosis; has effects in promoting synthesis of hemoglobin and hematopoiesis. Chromium element < 50 indicates that the human body is lack of chromium for a long time, and chromium element > 100 indicates that the human body takes too much chromium for a short time or the utilization rate of chromium in the human body is not high. Both too high and too low values of elemental chromium levels were found to be detrimental to blood glucose regulation.
According to the present invention, the measurement of vitamins and trace elements as described above can be carried out by a method known in the art, and preferably, the present invention is carried out by a biological weak magnetic field measurement analyzer (for example, Elder AGEREADER). The analyzer for measuring weak magnetic field of living body is based on quantum medicine and quantum physics as theory, and adopts normal temp. magnetic field resonance interferon generation system to analyze and interpret the different magnetic field information contained in human body tissue and organ so as to sense the function state of every tissue and organ of body.
According to the present invention, in order to further improve the accuracy of the diabetes risk assessment, it is preferable that the system further comprises: a biological activity measuring unit 4 and/or an interstitial insulin level measuring unit 5 of the liver and/or the pancreas.
Biological activity measuring unit 4 for liver and/or pancreas
In the invention, the biological activity values of the liver and the pancreas are limited to-20 to +20, which indicates normal functions. If the test result deviates from this range, it means that the risk of blood glucose fluctuation is gradually increased, the larger the magnitude of the index fluctuation, the higher the risk of blood glucose fluctuation, and the larger the number of index changes, the higher the risk of blood glucose fluctuation.
Wherein, the liver activity value is-20 to +20, and the liver is colorless and transparent, which indicates that the liver function is normal; -21 to +60, indicating enhanced liver function, ongoing inflammatory injury to the liver, increased risk of or ongoing development of hepatitis, fatty liver, alcoholic liver injury, pharmaceutical liver injury, biliary elimination disorder, and nutritional hepatitis, all of which may affect normal metabolism of blood glucose. -21 to-60 show a blue color, indicating reduced liver function, dysfunction of liver function, affecting normal sugar metabolism. 61 to-100, indicating decreased liver function, indicating liver fibrosis has developed and abnormal carbohydrate metabolism may occur.
Pancreatic bioactivity value: -20 to +20, which showed colorless and transparent, and normal pancreatic function. +21 to +60, the pancreas shows yellow color, suggesting dysglycemia, insulin resistance, suggesting risk of diabetes or early stage diabetes. +61 to +100, showing a red color, enhanced pancreatic function, significantly increased risk of developing diabetes or already having diabetes. -21 to-60 show a blue color, indicating a slight decrease in islet function, considering the risk of insulin resistance, impaired glucose metabolism, elevated blood glucose. -61 to-100, indicating a significant decrease in islet function, suggesting a significant increase in islet resistance and risk of diabetes.
Interstitial insulin level measuring unit 5
Interstitial insulin levels (N): the present invention defines a normal range of-20 < N < + 20. Increase out of the normal range: indicating insulin resistance, glucose metabolism disorder and abnormal blood sugar; out of the normal range: suggesting the risk of dysglycemia and blood sugar rise.
According to the present invention, body oxygen free radical levels, liver and/or pancreatic biological activity, and interstitial insulin levels can be measured using a bioelectrical whole body scanning system, for example, a bioelectrical whole body health scanning system (model: eagle exercise E.I.S. -01-USB). The bioelectricity whole-body health scanning system adopts a low-voltage direct-current stimulation induction technology, continuously sends self-adaptive and automatically-adjusted low-voltage (1.28V) direct-current signals which are uniformly arranged at 255 times per 3 seconds to individual areas of a human body 22 through 6 electrodes symmetrically arranged on the forehead, hands and feet, the electric signals are converted into ion flows in human tissues, and resistance, electric conductivity, PH value and voltage which penetrate through the tissues and action potentials which penetrate through cell membranes are obtained according to the polarization motion of the ion flows at the cathode and the anode, so that the electrophysiological activities of interstitial cells of various organs of the human body are activated. And according to the one-way conductivity of the physiological feedback signal, performing real-time current analysis, acquiring human body function information in a digital form, and performing 3D reconstruction on data through a digital model. The comprehensive function evaluation of each tissue and each organ of the whole body can be carried out within a few minutes.
According to the present invention, in order to further improve the accuracy of the diabetes risk assessment, it is preferable that the system further comprises a body tissue glycosylation detection unit 6.
Body tissue glycosylation detection unit 6
Advanced glycosylation end products are a general term for a group of highly active end products formed by a non-enzymatic glycosylation reaction (also called Maillard reaction) between amino groups of proteins, fatty acids or nucleic acids and aldehyde groups of reducing sugars. The accumulation of AGEs in the body can lead to diabetes and various complications. The higher the value of the glycosylation end products per 1 year of age means that the body has a reduced ability to regulate blood sugar and is more likely to have an increased blood sugar level.
The glycosylation can be detected by a glycosylation end product detector (model: MARATECH QFS-3401), and the glycosylation end product detector can be used for early warning the occurrence and development of diabetes, nephropathy, neuropathy, cardiovascular disease, retinopathy and musculoskeletal disease risks by detecting the level of glycosylation end products AGEs in a body. AGEs have been internationally recognized as an independent predictor of diabetes and its complications. The working principle is that an automatic fluorescence noninvasive detection method is initiatively adopted internationally, and the level of AGEs in vivo is measured and calculated by automatically absorbing fluorescence emitted by AGEs in human tissues, so as to evaluate the risk of diabetes and complications thereof.
According to the present invention, in order to further improve the accuracy of the diabetes patient risk assessment, it is preferred that the system further comprises a body tissue metabolic heat determination unit 7 and/or a body muscle and/or fat level determination unit 8.
Body tissue metabolism heat measuring unit 7
In the early stage of the disease, cellular metabolism is abnormal, which shows the abnormality of metabolic substances and metabolic heat, at this time, the abnormal accumulation of the metabolic substances may not reach the level clearly checked by the prior art, but the metabolic heat can be transferred from the body without long-term accumulation and checked by an infrared thermal imaging diagnostic apparatus, and the abnormal characteristic can be mastered through thermal fault reduction. It is found that energy metabolism also shows self characteristics in early stage of diabetes, and can be shown as abnormal metabolism of pancreas regions, low metabolic heat level of nose tip and hands and feet, low metabolic heat level or high metabolic heat level and the like.
The invention limits abnormal metabolic heat in the pancreatic region, wherein the delta F of the metabolic heat is more than or equal to 0.3 compared with the normal peripheral metabolic heat, and the lower or higher metabolic heat of the tail finger knuckle (finger pulp) means that the risk of blood sugar increase is increased.
The metabolic heat can be tested by an infrared thermal imaging diagnostic apparatus (model: Beijing Beibeiyi TSI-2000), the infrared thermal imaging diagnostic apparatus can comprehensively evaluate the metabolic state of each large system of the whole body, dynamically monitor, provide functional imaging basis for early detection and differential diagnosis of major diseases such as cardiovascular and cerebrovascular diseases, tumors and the like or chronic diseases, and provide curative effect monitoring data for the treatment and chemoradiotherapy effects after tumor operation, the change of the functions of organs to be treated after drug administration and operation and the like. The working principle focuses on the thermal metabolism condition of tissues and cells, the health condition of a human body is evaluated according to the thermal radiation difference of normal and abnormal tissue regions, potential necessary relation is found out, the human body condition is comprehensively evaluated, and a basis is provided for early disease discovery, systemic treatment effect and the like.
Body muscle and/or fat level determination unit 8
Body fat percentage: the male standard is 10-20%, the male standard is thin when the male standard is less than 10%, the male standard is mild and exceeds the standard when the male standard is 20-25%, and the male standard is obese when the male standard is more than 25%. The female standard is 20-30%, the female standard is lean when the female standard is less than 20%, the female standard is slightly out of standard when the female standard is 30-35%, and the female standard is obese when the female standard is more than 35%. The larger the value, the more elevated the risk of blood glucose is likely to occur.
Muscle: since muscle is the major tissue that consumes basal metabolism, muscle mass determines the basal metabolic rate. I.e., a person of the same weight, the greater the muscle mass, the higher the basal metabolic rate. As the muscle mass changes, the energy consumption also changes, and as the energy consumption decreases, fat tends to accumulate excessively, and the sensitivity to insulin decreases, leading to an increase in blood sugar and other diseases.
According to the present invention, the muscle mass is reduced, and the more fat is out of tolerance, and the fat distribution is in visceral type and apple type, the higher the risk of suffering diabetes.
Wherein, the muscle and/or fat level of the organism can be measured by a human body composition tester (model: Bailida Tanita MC-980MA), and the human body composition tester can detect the measured values of multiple indexes of human body such as water, protein, muscle, fat, bone mass and the like, and multiple indexes of fat ratio, body fat percentage, intracellular and extracellular fluids and the like of left and right upper limbs, left and right lower limbs, trunk and the like. Providing scientific data for weight control, fat reduction, muscle training, reasonable nutrition, scientific sports and the like. The working principle is that a Bioelectrical Impedance Analysis (BIA) method is adopted, eight-point contact electrodes are utilized, and a multi-loop method is utilized to comprehensively analyze multiple body components of a human body.
Nutritional exercise advice
According to the present invention, the more the above index deviates from the normal range, indicating the higher the risk of diabetes, the present invention gives the following nutritional exercise advice for subjects at higher risk of diabetes.
And (4) nutrition suggestion: including daily dietary adjustments and nutrient enrichment adjustments.
First, it is a proposal in the regulation of daily diet.
Referring to the general population dietary guideline of Chinese resident balance dietary guideline (2016), three diets in one day are reasonably arranged, and the following are made:
firstly, the fat intake is limited, and high-quality protein is properly selected.
② the fat intake should account for 20-25% or even less of the total energy, the intake of saturated fatty acid should be controlled, the intake of cholesterol should be controlled below 300mg per day. Protein is the material basis of life and also provides a certain amount of heat energy. The protein consumption of the diabetics per day is large and easy to lack; the intake is 1.0g/Kg body weight/day, wherein 40% -50% should be derived from high quality protein such as soybean protein.
And thirdly, balanced diet and selection of diversified and reasonably-nutritious foods.
Fourthly, the cereals, the vegetables, the fruits, the meat, the poultry, the fish, the milk, the eggs, the beans and the grease can be ingested uniformly every day, and the people cannot eat preferentially. Staple food and thick and thin matching are realized; non-staple food, meat and vegetables.
Reasonably controlling total heat to reach or maintain ideal body weight.
Sixthly, fat cells in the body of the obese person are enlarged and increased, insulin sensitivity is reduced, and normal regulation of blood sugar is not facilitated.
And the inorganic salt, the vitamin and the dietary fiber are reasonable and sufficient.
The intake of sodium salt should be limited, and the daily dose should be controlled below 6 g. The daily intake of dietary fiber is preferably about 30 g. Antioxidant vitamins such as vitamin C, vitamin E, beta-carotene, etc. can be supplemented appropriately.
Ninthly, reducing or prohibiting foods of monosaccharide and disaccharide.
The monosaccharide and disaccharide in the chloride do not need digestive enzyme in the intestinal tract, and can be directly absorbed into blood to quickly raise blood sugar, so that the peripheral tissues are not sensitive to the action of insulin, and the disease condition is aggravated. Monosaccharide: glucose, galactose, fructose; and (3) disaccharide: sucrose, lactose, maltose.
Secondly, there are suggestions to enhance nutrient regulation.
Supplementing compound fungal polysaccharide, particularly compound fungal polysaccharide mainly comprising grifola frondosa and shiitake, is beneficial to repairing islet cells and improving insulin secretion; enhancing the sensitivity of peripheral cells to insulin; enhancing immunity, and preventing complications.
② a compound nutrient preparation for supplementing alfalfa powder (containing alfalfa fiber, coumarin, alfalfa saponin and other beneficial components), red yeast rice, lecithin, matcha and the like, and comprehensively regulating glycolipid metabolism by promoting fat metabolism and preventing endogenous and exogenous cholesterol and other links.
Supplying the nutrition of fruits and vegetables (rich in active plant biochemical, multiple vitamins and minerals). The nutrition proportion is reasonable, the nutrition is easy to be absorbed and utilized by human body, the microcirculation is improved, the blood sugar is adjusted, and the injury of the blood sugar rise to organism tissues is reduced.
Supplementing sheep liver peptide, albumin peptide, compound vitamin, compound mineral substance and the like, facilitating the promotion of liver metabolism function, increasing the glucose metabolism level and helping to regulate the blood sugar level.
Exercise advice
It is recommended that the exercise can be continued for 30-60 minutes each time, preferably 60-90 minutes after a meal, and 1-2 times per day. The exercise intensity is controlled in aerobic condition, and after 15 minutes of exercise, the body feels to start to generate heat, the breathing is slightly accelerated, the spirit is smooth, and the next day is not tired.
Power exercises (upper limb muscular power, abdominal muscular power, lower limb muscular power training, etc.) are suggested that increase muscle mass and muscle strength.
Is suitable for various healthy rhythms with high blood sugar, such as square dance, swimming, aerobic running, slow running, fast walking, Taiji boxing and the like.
Examples
100 suspected diabetes (clinically not diagnosed as diabetes, namely blood sugar is in a normal range, but having diabetes symptoms such as polydipsia, diuresis, polyphagia, emaciation and fatigue and weakness) and healthy people are selected respectively, and the oxygen free radical level, the vitamin B group level, the zinc element level, the potassium element level, the magnesium element level, the manganese element level, the chromium element level, the biological activity of liver and/or pancreas, the interstitial insulin level, the glycosylation of body tissues and the metabolic heat of body tissues of the people are tested, and the results are shown in table 1.
TABLE 1
As can be seen from the above table, although 100 suspected diabetes people are selected, more than 90% of the research objects have abnormal indexes after the system is used for detection, which indicates that the human body has poor blood sugar regulating capability and corresponds to the subjective feeling; after 100 healthy people are selected and detected by the system, all indexes are almost in a normal range. Thus, the system for evaluating the risk of the glucose metabolism and the diabetic complications is more accurate and comprehensive than the prior art evaluation.
According to the invention, through a comprehensive evaluation mode, through single-factor, multi-angle and multi-direction system comprehensive evaluation analysis, the accuracy is higher from comprehensive evaluation of free radical level, vitamin level and trace element level in organism metabolites, and preferably in combination with various data such as liver and pancreas bioactivity values, interstitial insulin level, glycosylation end product value, heat metabolism level, muscle fat ratio and the like, so that scientific data support is provided for predicting the capability of regulating blood sugar of a human body, the method is favorable for knowing blood sugar change in advance, and nutrition and exercise intervention is carried out in time, and a great help effect is provided for avoiding diabetes and complications thereof.
The preferred embodiments of the present invention have been described in detail above with reference to the accompanying drawings, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention. Including each of the specific features, are combined in any suitable manner. The invention is not described in detail in order to avoid unnecessary repetition. Such simple modifications and combinations should be considered within the scope of the present disclosure as well.
Claims (10)
1. A system for assessing the risk of glucose metabolism and diabetic complications, the system comprising: the device comprises an organism oxygen free radical level measuring unit (1), an organism metabolite vitamin level measuring unit (2) and an organism metabolite microelement level measuring unit (3).
2. The system according to claim 1, wherein the vitamin level determination unit (2) in the body metabolites comprises a vitamin B group level determination module.
3. The system according to claim 1 or 2, wherein the determination unit (3) for the level of trace elements in the body metabolites comprises a zinc element level determination module.
4. The system according to claim 1 or 2, wherein the determination unit (3) for the level of trace elements in the body metabolites comprises a potassium level determination module.
5. The system according to claim 1 or 2, wherein the determination unit (3) for the level of trace elements in the body metabolites comprises a magnesium level determination module.
6. The system according to claim 1 or 2, wherein the determination unit (3) for the level of trace elements in the body metabolites comprises a manganese level determination module.
7. The system according to claim 1 or 2, wherein the determination unit (3) of the level of trace elements in the body metabolites comprises a module for determining the level of chromium elements.
8. The system of any one of claims 1-7, wherein the system further comprises: a liver and/or pancreas bioactivity determination unit (4) and/or an interstitial insulin level determination unit (5).
9. The system of any one of claims 1-8, wherein the system further comprises: and a body tissue glycosylation detection unit (6).
10. The system of any one of claims 1-9, wherein the system further comprises: a body tissue metabolism heat measuring unit (7) and/or a body muscle and/or fat level measuring unit (8).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810645169.0A CN110634567A (en) | 2018-06-21 | 2018-06-21 | System for assessing risk of carbohydrate metabolism and diabetic complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810645169.0A CN110634567A (en) | 2018-06-21 | 2018-06-21 | System for assessing risk of carbohydrate metabolism and diabetic complications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110634567A true CN110634567A (en) | 2019-12-31 |
Family
ID=68967739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810645169.0A Pending CN110634567A (en) | 2018-06-21 | 2018-06-21 | System for assessing risk of carbohydrate metabolism and diabetic complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110634567A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437503A (en) * | 2006-02-21 | 2009-05-20 | 阿斯特鲁姆医疗有限公司 | Compositions to reduce blood glucose levels and treat diabetes |
| CN105879230A (en) * | 2014-12-25 | 2016-08-24 | 王新展 | Chinese and western medicine integrated diabetes therapeutic instrument |
-
2018
- 2018-06-21 CN CN201810645169.0A patent/CN110634567A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437503A (en) * | 2006-02-21 | 2009-05-20 | 阿斯特鲁姆医疗有限公司 | Compositions to reduce blood glucose levels and treat diabetes |
| CN105879230A (en) * | 2014-12-25 | 2016-08-24 | 王新展 | Chinese and western medicine integrated diabetes therapeutic instrument |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hazell et al. | Two minutes of sprint-interval exercise elicits 24-hr oxygen consumption similar to that of 30 min of continuous endurance exercise | |
| Wilborn et al. | Effects of zinc magnesium aspartate (ZMA) supplementation on training adaptations and markers of anabolism and catabolism | |
| Cureton et al. | Dietary quercetin supplementation is not ergogenic in untrained men | |
| Gam et al. | Opposition of carbohydrate in a mouth-rinse solution to the detrimental effect of mouth rinsing during cycling time trials | |
| Bui et al. | Pre-germinated brown rice reduced both blood glucose concentration and body weight in Vietnamese women with impaired glucose tolerance | |
| Parcell et al. | Cordyceps Sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance | |
| Wallis et al. | Is there a specific role for sucrose in sports and exercise performance? | |
| ES2365138T3 (en) | COMPOSITION OF DIAGNOSIS FOR TYPE 2 DIABETES AND GLUCOSE INTOLERANCE, AND METHODS OF USE. | |
| CN103238840A (en) | Ginkgo biloba extract and fish oil soft capsule and preparation method thereof | |
| CN104026563A (en) | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof | |
| Sweazea et al. | Nitrate-rich fruit and vegetable supplement reduces blood pressure in normotensive healthy young males without significantly altering flow-mediated vasodilation: a randomized, double-blinded, controlled trial | |
| El-Sayed et al. | Effects of carbohydrate feeding before and during prolonged exercise on subsequent maximal exercise performance capacity | |
| Jia | Diatetic and exercise therapy against diabetes mellitus | |
| Miyamoto et al. | Gender difference in metabolic responses to surface electrical muscle stimulation in type 2 diabetes | |
| Morita et al. | Clinical evaluation of changes in biomarkers by oral intake of NMN. | |
| Imamura et al. | Effect of moderate exercise on excess post-exercise oxygen consumption and catecholamines in young women | |
| Ben Dhia et al. | Melatonin reduces muscle damage, inflammation and oxidative stress induced by exhaustive exercise in people with overweight/obesity | |
| WO2014143080A1 (en) | Methods for generating personalized dietary guidance using fatty acids for purposes of reducing risk of pathology | |
| CN110634567A (en) | System for assessing risk of carbohydrate metabolism and diabetic complications | |
| Lundström et al. | Changes in vitamin D status in overweight middle-aged adults with or without impaired glucose metabolism in two consecutive Nordic summers | |
| Pryor et al. | Hydration status and sodium balance of endurance runners consuming postexercise supplements of varying nutrient content | |
| Negro et al. | Essential amino acids (EAA) mixture supplementation: effects of an acute administration protocol on myoelectric manifestations of fatigue in the biceps Brachii after resistance exercise | |
| Jain et al. | Effect of 12week zumba program and healthy diet on anthropometry, body composition and fitness parameters in working women | |
| Wika et al. | Astaxanthin Reduces Heart Rate and Carbohydrate Oxidation Rates During Exercise in Overweight Individuals | |
| Zak-Golab et al. | The influence of weight loss on anaerobic threshold in obese women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191231 |
|
| WD01 | Invention patent application deemed withdrawn after publication |